Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 617-219-8 | CAS number: 81334-34-1
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Basic toxicokinetics
Administrative data
- Endpoint:
- basic toxicokinetics in vivo
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- test procedure in accordance with generally accepted scientific standards and described in sufficient detail
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 994
- Report date:
- 1994
Materials and methods
- Objective of study:
- metabolism
Test guideline
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- EPA OPP 85-1 (Metabolism and Pharmacokinetics)
- Deviations:
- no
- GLP compliance:
- yes
Test material
- Test material form:
- solid
Constituent 1
- Specific details on test material used for the study:
- SOURCE OF TEST MATERIAL
- Source and lot/batch No.of test material: AC 5561-133
- Purity: 99.5 %
RADIOLABELLING INFORMATION
- Radiochemical purity: 96.8%
- Specific activity: 43.41 µCi/mg
- Locations of the label: Pyridine ring 6-carbon - Radiolabelling:
- yes
- Remarks:
- 14C
Test animals
- Species:
- rat
- Strain:
- Sprague-Dawley
- Remarks:
- Crl:CD BR
- Details on species / strain selection:
- The laboratory rat is selected as a suitable model species for human exposure through the food chain; the rat is also a preferred mammalian species specified in the EPA Study Guidelines 85-1.
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Breeding Laboratories, Wilmington, Massachusetts, USA
- Age at study initiation: 6 to 10 weeks
- Weight at study initiation: 200 ± 50 g
- Housing: individual glass metabolism cages constructed to allow for separate collection of urine and faeces.
- Diet: ad libitum
- Water: tap water ad libitum
- Acclimation period: 7 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 20 ± 4
- Humidity (%): 50 ± 20
- Photoperiod (hrs dark / hrs light): 12/12
Administration / exposure
- Route of administration:
- other: oral gavage and intravenous
- Vehicle:
- corn oil
- Details on exposure:
- PREPARATION OF DOSING SOLUTIONS: The radiolabeled test item was dissolved in corn oil for all oral dosing solutions and intravenous dosing solution was prepared in normal saline solution.
- Duration and frequency of treatment / exposure:
- Group A: oral gavage single low dose
Group B: oral gavage single high dose
Group C: Mutiple Oral Low Dose (14 days)
Group D: single intravenous Dose
Group E: Control Group (oral gavage single dose)
Doses / concentrationsopen allclose all
- Dose / conc.:
- 9.5 mg/kg bw/day (nominal)
- Remarks:
- oral gavage single dose
- Dose / conc.:
- 924 mg/kg bw/day (nominal)
- Remarks:
- oral gavage single dose
- Dose / conc.:
- 10 mg/kg bw/day (nominal)
- Remarks:
- oral gavage daily for 14 days (unlabelled test item), followed by single dose labelled test item (9.26 mg/kg bw)
- Dose / conc.:
- 9.94 mg/kg bw/day (nominal)
- Remarks:
- intravenously administered
- Dose / conc.:
- 0 mg/kg bw/day (nominal)
- Remarks:
- single dose vehicle only (1 mL corn oil)
- No. of animals per sex per dose / concentration:
- Group A - D: 5
Group E: 2 - Control animals:
- yes, concurrent vehicle
- Positive control reference chemical:
- Not applicable
- Details on study design:
- - Dose selection rationale: A preliminary study has been conducted. Furthermore, the low dose corresponds to a NOEL which is consistent with a teratology study in rats and will provide for an appropriate intravenous dosage.
- Details on dosing and sampling:
- TOXICOKINETIC / PHARMACOKINETIC STUDY (Absorption, distribution, excretion)
- Tissues and body fluids sampled: urine, faeces, (blood, bone-femur, brain, fat-reproductive area, skin-shaved, testes, ovaries, heart, kidneys, liver, lungs, muscle-thigh, spleen and residual carcass,
- Time and frequency of sampling: 0-4, 4-8, 8-12, 12-24, 24-36, 36-48, 48-72, 72-96, 96-120, 120-144, and 144-168 hours post-dosing
METABOLITE CHARACTERISATION STUDIES
- Tissues and body fluids sampled: urine, faeces
- Time and frequency of sampling: Day 1 and Day 2
- From how many animals: samples pooled per sex/group
- Method type(s) for identification: HPLC, TLC - Statistics:
- limited to mean and standard deviation
Results and discussion
- Preliminary studies:
- Results from the preliminary study indicated that approximately 72 % to 75 % of the 14C-test item-related radioactivity was excreted in the urine and cage rinse over a 3-day period. About 19 % to 20 % was excreted in the feces. Expired air contained 0.06 % to 0.12 % of the dosed radioactivity. An average of ~90 % of the dosed radioactivity was excreted within the first 24 hours. The excretion pattern was similar in both male and female rats. The excretion pattem and quantity for this 72-hour period is consistent with those of the oral low dose groups in the definitive study.
Main ADME resultsopen allclose all
- Type:
- excretion
- Results:
- The majority of the administered dose was excreted mainly as intact item in faeces and urine (78.3 % to 96.0 %) in the first 24 h.
- Type:
- metabolism
- Results:
- Two metabolites (the substituted and nonsubstituted 2-carbamoyl derivatives) accounted for 0.24 % and 0.15 % of urine, respectively.
Toxicokinetic / pharmacokinetic studies
- Details on absorption:
- The calculated percent of absorption in the oral dose groups was 80.6% and 80.0% for single-dose males and females, respectively, and 75.6% and 71.4% for multiple-dose males and females, respectively.
- Details on distribution in tissues:
- Analysis of rat tissues and organs (blood, bone-femur, brain, fat-reproductive area, skin-shaved, testes, ovaries, heart, kidneys, liver, lungs, muscle-thigh, spleen and residual carcass) showed that TRR levels were below detection limits except in carcass (<0.01 - 0.87 ppm) and high dose liver (0.45 ppm in female rats) and kidney (0.36 ppm for male rats and 0.52 ppm for female rats) and multiple dose ovaries (0.03 ppm). Total radioactive residue levels in control (untreated) animal samples were all less than the validated minimum quantifiable limit of detection.
- Details on excretion:
- A majority of the administered dose was eliminated in urine (67.8 %-94.6 %) and, to a lesser extent, in feces (5.5 %-33.2 %) over a 7-day period following dosing. Most of the elimination occurred within the first 24 hours post treatment.
Metabolite characterisation studies
- Metabolites identified:
- yes
- Details on metabolites:
- Two metabolites (the substituted and nonsubstituted 2-carbamoyl derivatives) accounted for 0.24 % and 0.15 % of urine, respectively. Low, but detectable, levels of several unknown metabolites (0.21 to 5.65 % of urine) were also found in urine samples; however none of the individual unknown metabolites exceeded 0.11 % of urinary radiocarbon.
Any other information on results incl. tables
Table 1: Cumulative Amount of Radioactivity at Specified Intervals after Rats Were Dosed with 14C-Test item – Percent of Radioactive Dose in Urine
Collection Interval (hours) |
Group A |
Group A |
Group B |
Group B |
Group C |
Group C |
Group D |
Group D |
|
Male |
Female |
Male |
Female |
Male |
Female |
Male |
Female |
0- 4 |
39.4 |
12.2 |
14.4 |
21.5 |
20.3 |
17.6 |
66.2 |
41.2 |
0- 8 |
63.5 |
27.4 |
62.5 |
55.1 |
39.5 |
30.9 |
86.7 |
70.0 |
0-12 |
69.3 |
60.0 |
69.8 |
62.3 |
58.6 |
44.8 |
88.8 |
72.6 |
0-24 |
73.7 |
67.7 |
74.5 |
68.3 |
68.9 |
56.9 |
90.6 |
75.0 |
0-36 |
75.2 |
70.2 |
75.4 |
69.5 |
70.8 |
59.7 |
91.3 |
75.5 |
0-48 |
76.3 |
71.9 |
75.9 |
70.3 |
71.7 |
61.0 |
91.8 |
76.8 |
0-72 |
77.1 |
72.9 |
76.2 |
71.6 |
72.2 |
62.1 |
92.3 |
77.7 |
0-96 |
77.5 |
73.6 |
76.5 |
72.1 |
72.6 |
62.6 |
92.5 |
78.6 |
0-120 |
77.7 |
73.8 |
76.6 |
72.6 |
72.9 |
63.1 |
92.6 |
78.9 |
0-144 |
77.9 |
74.1 |
76.8 |
72.9 |
73.0 |
63.4 |
92.7 |
79.1 |
0-168 |
81.1 |
78.5 |
78.8 |
76.7 |
75.0 |
67.8 |
94.6 |
86.5 |
Table 2: Cumulative Amount of Radioactivity at Specified Intervals after Rats Were Dosed with 14C-Test item – Percent of Radioactive Dose in faeces
Collection Interval (hours) |
Group A |
Group A |
Group B |
Group B |
Group C |
Group C |
Group D |
Group D |
|
Male |
Female |
Male |
Female |
Male |
Female |
Male |
Female |
0- 4 |
0.4 |
<0.01 |
<0.01 |
<0.01 |
0.1 |
0.1 |
2.7 |
<0.01 |
0- 8 |
1.1 |
<0.01 |
0.2 |
<0.01 |
0.1 |
0.7 |
4.0 |
<0.01 |
0-12 |
5.3 |
0.1 |
2.0 |
0.1 |
0.4 |
1.2 |
4.3 |
0.2 |
0-24 |
22.7 |
20.3 |
18.8 |
17.9 |
23.8 |
23.3 |
5.4 |
3.0 |
0-36 |
24.4 |
22.6 |
19.9 |
20.0 |
27.5 |
27.5 |
5.9 |
3.4 |
0-48 |
25.3 |
24.0 |
20.6 |
20.6 |
29.4 |
30.7 |
6.2 |
3.6 |
0-72 |
25.8 |
24.7 |
20.8 |
21.1 |
30.1 |
31.5 |
6.3 |
4.7 |
0-96 |
26.0 |
25.3 |
20.8 |
21.3 |
30.5 |
32.0 |
6.4 |
4.9 |
0-120 |
26.2 |
25.4 |
21.0 |
21.7 |
30.8 |
32.2 |
6.6 |
5.1 |
0-144 |
26.3 |
25.6 |
21.1 |
21.8 |
30.9 |
33.1 |
6.6 |
5.2 |
0-168 |
26.4 |
25.9 |
21.1 |
21.9 |
31.1 |
33.2 |
6.6 |
5.5 |
Applicant's summary and conclusion
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.

Welcome to the ECHA website. This site is not fully supported in Internet Explorer 7 (and earlier versions). Please upgrade your Internet Explorer to a newer version.
This website uses cookies to ensure you get the best experience on our websites.
Find out more on how we use cookies.